Scientists have welcomed the “extremely encouraging” results of Janssen’s new single-shot Covid-19 vaccine trial announced less than 24 hours after the Novavax jab also appeared effective.
The vaccine, developed by the Johnson & Johnson-owned pharmaceutical firm, is 66% effective overall at preventing moderate to severe coronavirus 28 days after vaccination, trial results show.
Novavax announced late on Thursday that its jab was 89% effective following a clinical trial run in the UK.
The results come as January 30 marks the anniversary of the first known death involving Covid-19 in the UK, that of 84-year-old Peter Attwood, from Chatham in Kent.
One year on, the Government on Friday said the death total now stands at 104,371 after reporting a further 1,245 people had died within 28 days of testing positive for Covid-19.
Separate figures published by the UK’s statistics agencies for deaths where Covid-19 has been mentioned on the death certificate, together with additional data on deaths that have occurred in recent days, show there have now been 121,000 deaths involving Covid-19 in the UK.
Experts say the latest vaccine data is another positive sign, with three jabs already approved for use in the UK – Pfizer/BioNTech, Moderna and Oxford/AstraZeneca.
Professor Kevin Marsh, co-lead of the Covid-19 team at the African Academy of Sciences, and Professor of Tropical Medicine at the University of Oxford, said the results from the Janssen jab trials were “extremely encouraging”.
He said: “It is possible that some people will look at the overall reported efficacy of 66% in preventing moderate to severe Covid-19 and focus on comparisons with potentially higher ‘top line’ efficacy reported for some other vaccines.
“This would be a mistake. The real headline result is that a single-shot vaccine, capable of easy long-term storage and administration, provided complete protection against hospitalisation and death.”
The UK has ordered 30 million doses of the vaccine, with the option of 22 million more, with deliveries expected in the second half of this year if the jab is approved by the Medicines and Healthcare products Regulatory Agency (MHRA).
Some 60 million doses of the Novavax jab, to be produced on Teesside, have also been secured, with the hope that the MHRA could approve it within weeks.
Janssen is continuing trials into two doses of its vaccine to see whether this produces an even higher efficacy.
GOOD NEWS on the single-dose Janssen vaccine
Our approach of buying abroad & making here in the UK is paying off & I want to say a huge THANK YOU to everybody involved 🇬🇧 pic.twitter.com/X5n2Hw2nfR
— Matt Hancock (@MattHancock) January 29, 2021
Health Secretary Matt Hancock tweeted: “This is yet more good news from Janssen on vaccines.
“If this jab is approved this could significantly bolster our vaccination programme, especially as a single-dose vaccine.”
Johnson & Johnson plans to file for regulatory approval in the US next week, followed shortly by applying for approval in Europe and the UK.
However, the latest Government figures suggest the growth rate, which estimates how quickly the number of infections is changing day by day, is between minus 5% and zero for the UK as a whole.
It means the number of new infections in the UK is broadly flat or shrinking by up to 5% every day.
The Scientific Advisory Group for Emergencies (Sage) said the estimates are based on the latest data, available up to January 25, including hospital admissions and deaths as well as symptomatic testing and prevalence studies.
But it warned that cases “continue to be dangerously high and the public must remain vigilant to keep this virus under control, to protect the NHS and save lives”.
Meanwhile, 8,369,438 coronavirus jabs have been given in the UK as of January 28, of which 7,891,184 were first doses – a rise of 443,985 on the previous day’s figures.
The seven-day rolling average of first doses given in the UK is now 358,297.
Based on the latest figures, an average of 418,166 first doses of vaccine would be needed each day in order to meet the Government’s target of 15 million first doses by February 15.